.A Phase I Study to Evaluate the Safety/Tolerability and Immunogenicity of V930/V932 in Patients with Cancers Expressing HER-2 and/or CEA

Trial Profile

.A Phase I Study to Evaluate the Safety/Tolerability and Immunogenicity of V930/V932 in Patients with Cancers Expressing HER-2 and/or CEA

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Apr 2013

At a glance

  • Drugs V 932 (Primary) ; V-930 (Primary)
  • Indications Breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 20 May 2009 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.
    • 20 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top